key: cord-0981571-3lqs4pf6
authors: Coltart, Cordelia E.M.; Collet-Fenson, Luke
title: Future developments in prevention, diagnosis and treatment of COVID-19
date: 2021-03-27
journal: Best Pract Res Clin Obstet Gynaecol
DOI: 10.1016/j.bpobgyn.2021.03.012
sha: 51e47d65cf9843e591f93203430873b2abac65e1
doc_id: 981571
cord_uid: 3lqs4pf6

The impact of the COVID-19 pandemic has been profound and global. Mitigating future waves and overcoming this pandemic is a global public health priority. This review focuses on future developments in prevention, diagnosis and treatment of COVID-19, which may help to address these current challenges. The specific relevance to women’s and maternal health, addressing the vulnerabilities in this group, is considered. The remarkable scientific achievements that have been made with respect to the development and implementation of both vaccines and therapeutics for COVID-19 are highlighted. The speed and processes for the development, approval and implementation of interventions heralds a new way forward for combating emerging infectious diseases. However, it is important to note that this it is a rapidly changing field with a constantly evolving knowledge base.

In December 2019, the first documented cases of an unknown disease were reported in Wuhan, China. However, reports now suggest that cases may have been present six months before the official documented case. 1-4 The causative organism was subsequently identified to be a novel coronavirus named SARS-CoV-2, which results in a clinical disease called Coronavirus Disease 2019 . Cases quickly spread worldwide and COVID-19 was classified by the World Health Organisation (WHO) as a global pandemic on 11 th March 2020. As of 13 th February 2020 there have been approximately 107.7 million reported cases and nearly 2.4 million deaths of COVID-19 in 214 countries. 5 In England, there have been just over 4 million confirmed cases and 102,562 deaths (116,287 deaths in the UK). 6 The impact has been profound, both in England and globally.

This review focusses on future developments in the prevention, diagnosis and treatment of COVID-19. We detail both current practices as well as future developments, including those of specific relevance to women's and maternal health. The UK has been lauded globally for its approach to COVID-19 research and has made substantial scientific contributions, 7 particularly towards the fields of vaccines and therapeutics for COVID-19. These remarkable achievements are detailed and will likely play a substantial role in overcoming this pandemic and mitigating future waves, which are global public health priorities.

Much of the information in this article is generalisable and not specific to pregnant women, for example preventative measures apply to all. However, there are specific circumstances which apply to obstetric patients as pregnancy is a time of vulnerability. In brief, they are not thought to be more susceptible to COVID-19 infection than the general population, despite the degree of immunosuppression associated with pregnancy, but they may be more vulnerable to severe infection and resultant medical complications, particularly in third trimester. 8 There is no good quality evidence comparing the risk of severe COVID-19 infection in pregnant women and nonpregnant women of the same age. 9 Furthermore, COVID-19 may lead to an increase in pre-term births 10,11 . Additionally, good antenatal care demands regular hospital antenatal appointments, which may bring additional risks in increasing contacts and potential exposures. Thus, there is additional emphasis on ensuring their safety. This article aims to draw out factors relevant to a women's health audience. This is still a relatively new disease and it is a rapidly changing field with a constantly evolving knowledge base. Therefore, this paper presents the current evidence base at the time of submission, J o u r n a l P r e -p r o o f but will be superseded/outdated as the science evolves, particularly with respect to therapeutics and vaccines, where new information is emerging on a weekly basis. outline the general prevention advice for the general public. However, there is currently limited evidence to confidently quantify the absolute risk reduction attributed to each mitigation method and each measure is not recommended in isolation, but as part of a wider package of measures.

The recommendations are constantly changing as the pandemic and knowledge of the virus evolve.

Therefore, this section is focussed on the science underlying some of the key preventative measures, rather than a review of current practices 12 . Box 1 gives an overview of the key government preventative slogans used during the pandemic and Box 2 outlines the general infection prevention advice measure and non-pharmaceutical interventions which have formed the basis of the UK prevention campaign.

Box 2: Prevention advice and interventions General infection prevention advice  Hygiene measures: o Frequently wash hands with soap and water for at least 20 seconds or use an alcohol-based sanitiser (with >60% alcohol content). This is especially important after exposure to a public place, blowing nose, coughing/sneezing. o Avoid touching eyes, nose, and mouth with unwashed hands o Practice respiratory hygiene (i.e. cover mouth and nose when coughing or Box 1: Governm ent COVID J o u r n a l P r e -p r o o f sneezing with a tissue, discard the tissue immediately in a closed rubbish bin and then wash your hands) o Clean and disinfect frequently touched surfaces  Social distancing/minimising contacts:

o Avoid close contact with people. Aim to maintain a distance of at least 2 metres o Avoid shaking hands, especially with those who are unwell with a fever, cough or are sneezing o Avoid crowded and poorly ventilated places o Aim to maximise ventilation where possible o Restrict meeting members of other households according to current guidance e.g.

'Rule of six'  Isolation:

o Follow local isolation procedures, for example stay at home and self-isolate if you have any symptoms (even if mild). o Follow isolation procedures if you are a contact of a confirmed case  Facial coverings:

o Wear a facial covering according to local guidance Examples of non-pharmaceutical interventions implemented during local and national restrictions and lockdowns 13  Stay at home order  Contact within other households banned/ Limiting contact between members of different households: Including 'The Rule of Six'  Closure of schools (except for key workers and vulnerable children), childcare, colleges and universities closed.  Closure of places of worship  Restrictions on indoor/outdoor gatherings, and prohibiting large events  Encouragement to work from home wherever possible. Only essential workers permitted to attend workplace.  Closure of bars, pubs, cafes and restaurants  Closure of leisure and hospitality sector including gyms, sports centres etc  Closure of community centres  Closure of non-essential retail  Closure of close-contact personal services (hairdressing, beauty therapy etc)

Phyisical distancing is a key component in the control measures for COVID-19. However, the exact details of the distance and length of safe exposures in various settings remains unclear as multiple factors combine to determine the distribution of viral particle spread and, therefore, risk. The recommended distances differ between countries, with the UK and US recommending 2 metres, but other countries recommending 1 metre as sufficient. 14 The distance of 2 meters is controversial. 14 It stems from historical studies from other pathogens dating back to 1897, which proposed 1-2 metres as a safe distance from visible droplets containing pathogens. 15 Traditionally, respiratory infections are divided according to the size of the droplet, which will determine how far it will travel from an infected person: large droplets travel less far (1-2 metres) i.e. droplet spread, whereas small droplets J o u r n a l P r e -p r o o f i.e. aerosol or airborne spread (typically invisible ot the naked eye) can travel less far, but with airflow can spread greater distances. 14 This dichotomy misses the complexities of the continuum of viral partical size, respiratory exhalation factors and airflow, all of which can determine how far a particle will travel. 14,16 Research in 1948 on haemolytic streptococci found that 65% of participants (n=48) produced large droplets only and <10% travelled >1.7metres, 17 further reinforcing the concept of droplet infections and the 1-2 metre distance rule. However, recent systematic reviews show that respiratory droplets >60µm (SARS-CoV-2 virion is approximately 50-200µm in diameter)

can travel beyond two metres, 18 sometimes over 6-8 metres. 16, 19 Thus suggesting SARS-CoV-2 could spread beyond 1-2 meters, especially following coughing or sneezing. 14,16 Reports from other recent viral outbreaks (SARS-CoV-1, MERS-CoV and Avian flu) have also shown suspected spread beyond 2 metres. 20,21 Furthermore, hospital studies have suggested SARS-CoV-2 shows airborne spread. 14 When implementing a national recommendation, it is very difficult to account for all eventualities, therefore the decision should be practical, realistic and provide the best recommendation based on current knowledge. The Scientific Advisory Group for Emergencies (SAGE) reveiwed the evidence and estimated that the risk of SARS-CoV-2 transission at one metre could be 2-10 times higher than at two metres. 22 Therefore, UK guidance was based on 2 metres initially. A WHO systematic review showed that a physical distancing of <1m was reported to result in a transmission risk of 12.9%, compared to 2.6% at distances ≥1metre, supporting a distancing rule of one metre or more. 23 Other countries adopted this, and while current UK guidance retains the 2 metre criteria, it now also allows for a 1 metre distance with additional mitigations in some settings.

Recommendations for facial covering for source control vary between countries. 24 The transmission route for COVID-19 is via respiratory droplet infection and facial coverings, fully covering the mouth and nose, are considered a public health measure by providing a physical barrier to contain respiratory droplets and reduce transmission. 25 The wearing of a facial covering does not primarily protect the wearer from others, but protects others from you, provided the mask fits correctly and is made from optimal material. 26 They work best when used on a widespread scale with high compliance. In the UK, the recommendation is to wear a mask in specific indoor public situations and in all indoor places where social distancing may be difficult, unless one has an exemption. This is consistent with WHO advice to use a non-medical mask in areas of known or suspected tranmission. 27 The scientific evidence to support the widespread use of facial coverings (especially cloth masks) is evolving rapidly. However, the evidence base is lacking as the majority of studies have previously been conducted in healthcare settings with medical grade masks (FFP2/3) and focus on the protection of the wearer, 26,28 with the consensus that masks use leads to reduction in virus transmission. 29 However, there are caveats in generalising these results directly to community settings including the use of cloth coverings, poor technique, poor fitting and behavioural factors. 26 Furthermore, the evidence that does exist is based on a limited number of inconsistent observational studies 27 and those studies that did assess community mask use often did not distinguish between the different types of mask. 26, 30 A Cochrane review determined that the use of a mask made little or no difference to the number of people that caught influenza-like illnesses, although the evidence base was of poor quality and did not include current studies from the COVID-19 pandemic. 31 A further meta-analysis concluded a slight reduction in odds of respiratory infection. 32 The first randomised controlled trial to assess the efficacy of mask use in COVID-19 found that the use of a surgical mask outside the home did not reduce the incidence of SARS-CoV-2 infection compared to the no mask recommendation. 33 In contrast, recent work is more favourable towards mask use. A recent review offers evidence in favour of widespread mask use as source control to reduce community transmission. 34 Recent research by Centres for Disease Control (CDC) has suggested that double masking with a close fitting surgical mask worn under a cloth mask can significantly enhance protection against However, key questions remain on the effect of mask use on transmission and source control.

Despite the lack of definitive evidence, there is potential benefit and no risks associate with mask use, plus clearer evidence of benefit in healthcare settings. 28 Thus, the consensus is to recommend use.

Isolation of symptomatic cases, contact tracing and quarantining were used as early containment measures for COVID-19 in many countries. 36 These are old concepts that are used as standard public health containment measures for infectious disease outbreak from direct person-to-person transmission. 36 These interventions are designed to prevent those with the virus, or with a significant J o u r n a l P r e -p r o o f chance of having been infected, from transmitting the virus during the infectious period. However, not all cases will be detected as there are asymptomatic cases and false positive test results. The success of these containment measures depends on the transmission dynamics of the infection and the proportion of asymptomatic transmission. 37 Evidence suggests that in SARS-CoV-2, self-isolation alone would need to be achieved in a high proportion of cases and contacts to successfully limit the effective reproduction number (R<1). 36, 38 However, the proportion of asymptomatic cases reported in this pandemic is likely to hinder the success of self-isolation alone leading to successful reduction in cases. 39 If combined in a wider package of moderate social distancing measures, together with self-isolation and contact tracing, then control of SARS-CoV-2 transmission is more likely to be achieved. 36 Currently, in the UK those with symptoms of coronavirus or a positive test results for coronavirus are asked to immediately self-isolate for 10 days (previously 7 days), after which they will typically no longer be infectious. Their households and contacts are also asked to self-isolate for 10 days (previously 14 days). The isolation period for contacts was reduced as evidence suggested that the average incubation period was 5-6 days, with approximately 10% of cases developing illness after 10 days and 1-2% after 14 days. 40 People are most infectious in the 48hrs before developing symptoms and for approximately 5 days afterwards. 39, 41, 42 Thus, reduction in the isolation period may allow 10% of cases to leave isolation before symptom onset, but may increase compliance. 40 'COVID-safe' obstetric clinics:

Obstetric patients present a unique challenge during this pandemic. Not only do they have specific vulnerabilities, but they have numerous interactions with healthcare providers. Recent evidence suggests that nosocomial infections may have played a substantial role in the first wave of the pandemic, accounting for 40% of COVID-19 infections in hospital patients. 43 Furthermore, a report from a New York City hospital at the peak of the pandemic showed that following universal testing of all pregnant patients 15% were positive for COVID-19 and most were asymptomatic (87.9%). 44 Thus, safe obstetric care is essential and services need to adapt practices to protect mothers, babies, and healthcare workers during these challenging times. Many healthcare encounters have moved to telemedicine, however, this is not possible for many obstetric appointment including scans.

Therefore, other measures need to be considered and might include a universal testing programme with rapid point-of-care tests. Box 3 highlights some specific measures to ensure a 'COVID-safe' environment.

Box 3: Infection prevention and control (IPC) in healthcare settings to ensure a 'COVID-safe' J o u r n a l P r e -p r o o f environm ent  Follow local IPC guidelines and basic principles  Hand and respiratory hygiene  Wearing appropriate PPE for droplet precautions or airborne precautions if performing an aerosol-generating procedure: follow local guidance but PPE will vary according to situation/location, but should include mask, gloves, gown, eye protection/face shield o Specific local advice should be in place for precautions during labour when patients may be vocal, but it is difficult them to wear masks  Use of disposable equipment where possible  Limit the number of contacts, including healthcare providers, domestic and porter staff  Consideration of universal testing/screening when community prevalence is high  Isolation of suspected and confirmed cases o Place patients in a well ventilated single room is possible, or cohort together in same bay/area with at least 1 metre between patients 45 o Patients to wear medical mask o Safe waste management o Appropriate cleaning procedures  Telehealth consultations where possible and safe to do so J o u r n a l P r e -p r o o f

MERS vaccine technology to develop a COVID-19 vaccine

the government announced £20 million of further funding for clinical trials of the Oxford vaccine and the NIHR prioritised these clinical trials. This approach of considerable state support, linkage with industry (AstraZeneca), overlapping and heavily prioritised clinical trials brought this vaccine to J o u r n a l P r e -p r o o f ERROR: syntaxerror OFFENDING COMMAND: --nostringval